Clinical Trials

27 results for Kidney/Renal Cancer


Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders

  • Condition: Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Synd
  • Intervention: Procedure: Haploidentical Bone Marrow/Kidney
  • Study ID: NCT01758042
View Trial

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.

  • Condition: Thyroid Cancer, Medullary
  • Intervention: Drug: 177Lu-PP-F11N
  • Study ID: NCT02088645
View Trial

An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours

  • Condition: Carcinoma, Neuroendocrine
  • Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
  • Study ID: NCT01876771
View Trial

Phase Ib Trial Of Pembrolizumab And Nintedanib

  • Condition: Patients With Any Advanced Solid Tumors.
  • Intervention: Drug: Nintedanib, Drug: Pembrolizumab
  • Study ID: NCT02856425
View Trial

Kidney Cancer DNA Registry

  • Condition: Renal Cancer
  • Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
  • Study ID: NCT02087852
View Trial

Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT03647878
View Trial

Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study

  • Condition: Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
  • Intervention: Drug: Low dose of aspirin
  • Study ID: NCT03734614
View Trial

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

  • Condition: Renal Tumor
  • Intervention: Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03747133
View Trial

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

  • Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
  • Intervention: Drug: ATR Kinase Inhibitor AZD6738, Drug: Olaparib
  • Study ID: NCT03682289
View Trial

A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib

  • Condition: Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
  • Study ID: NCT03013946
View Trial

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab
  • Study ID: NCT03288532
View Trial

Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Other: Carevive software
  • Study ID: NCT03229083
View Trial

Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma

  • Condition: Kidney Cancer
  • Study ID: NCT03414827
View Trial

REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT04106349
View Trial

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

  • Condition: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell
  • Study ID: NCT04071223
View Trial

A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Study ID: NCT05468697
View Trial

A Phase 1/2, Open Label Dose-escalation and Expansion Trial of NKT2152, an Orally Administered HIF2α Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Condition: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
  • Study ID: NCT05119335
View Trial

A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  • Condition: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma,
  • Study ID: NCT05935748
View Trial

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers

  • Condition: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal C
  • Study ID: NCT05544929
View Trial

A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors

  • Condition: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
  • Study ID: NCT05462873
View Trial

Study of SRF388 in Patients With Advanced Solid Tumors

  • Condition: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma
  • Study ID: NCT04374877
View Trial

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Zeta Inhi

  • Condition: Advanced Solid Tumors
  • Study ID: NCT05614102
View Trial

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

  • Condition: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
  • Study ID: NCT05327686
View Trial

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

  • Condition: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer##
  • Study ID: NCT05864144
View Trial

A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

  • Condition: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head a
  • Study ID: NCT05708950
View Trial

Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings

  • Condition: Renal Malignant Tumor
  • Intervention: Drug: Contrast enhanced ultrasound with Lumason
  • Study ID: NCT03821376
View Trial

Multiomics Approach for Patients Stratification and Novel Target Identification in Metastatic Clear Renal Cell Carcnoma

  • Condition: Metastatic Clear Cell Renal Carcinoma
  • Study ID: NCT05782400
View Trial